Early nebivolol treatment is beneficial in myocardial infarction in rats partly through β3‐adrenoceptor remodelling
- 14 December 2020
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 48 (7), 1007-1015
- https://doi.org/10.1111/1440-1681.13447
Abstract
It remains unknown whether β‐blockers are useful and safe in acute myocardial infarction (MI). Owing to its pharmacological profile and vasodilating action, nebivolol (N) is useful in MI. The aim of the present study was to assess in rat whether early nebivolol treatment could be beneficial in MI. It remains unknown whether β‐blockers are useful and safe in acute MI. On day (D) 0, male Sprague‐Dawley rats underwent left coronary artery ligation (MI) or simple thoracotomy (SHAM). On D1 and D2, the rats were treated with either nebivolol (5 mg.kg−1.day−1, MI‐N and Sham‐N) or vehicle (V, MI‐V and Sham‐V). On D3, heart rate, left ventricle (LV) intrinsic contractility (PESmid) and arterial elastance were measured. Cardiac and aortic β‐Adrenoceptor (AR) subtype mRNA were quantified using real time quantitative RT‐qPCR. Catecholamine response was assessed on isolated heart and aortic rings with isoproterenol. PESmid was decreased in MI without worsening the decrease nebivolol. In LV, β1‐ and β3‐AR mRNA were respectively decreased and increased in all MI. β3‐AR mRNA increase was partly limited by nebivolol. Ex vivo, basal contractility was less decreased in MI‐N than in MI‐V. Isoproterenol response was only altered in MI‐V. In MI aorta, Nebi prevented β2‐ and β3‐AR mRNA increases. In addition, Acetylcholine‐induced relaxation was lowered in MI‐V but preserved with nebivolol. We demonstrated an early modulation of cardiovascular β3‐AR transcription early MI. Despite its putative negative inotropic properties, nebivolol did not worsen cardiac function in basal conditions and preserved LV catecholamine response.Keywords
Funding Information
- Fédération Française de Cardiologie
- Fondation France-Japon de l'EHESS
- Fondation Daniel Langlois pour l'Art, la Science et la Technologie
- Menarini Group
This publication has 31 references indexed in Scilit:
- Changes in One-Year Mortality in Elderly Patients Admitted with Acute Myocardial Infarction in Relation with Early ManagementThe American Journal of Medicine, 2017
- Nebivolol Protects against Myocardial Infarction Injury via Stimulation of Beta 3-Adrenergic Receptors and Nitric Oxide SignalingPLOS ONE, 2014
- Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockageAmerican Journal of Physiology-Heart and Circulatory Physiology, 2013
- Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart FailureCurrent Pharmaceutical Biotechnology, 2012
- Nebivolol Exerts Beneficial Effects on Endothelial Function, Early Endothelial Progenitor Cells, Myocardial Neovascularization, and Left Ventricular Dysfunction Early After Myocardial Infarction Beyond Conventional β1-BlockadeJournal of the American College of Cardiology, 2011
- Rabbit, a relevant model for the study of cardiac β3-adrenoceptorsExperimental Physiology, 2009
- Beta3-Adrenoceptor in the eel (Anguilla anguilla) heart:negative inotropy and NO-cGMP-dependent mechanismJournal of Experimental Biology, 2006
- The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle.JCI Insight, 1998
- Functional beta3-adrenoceptor in the human heart.JCI Insight, 1996
- Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failureJournal of the American College of Cardiology, 1991